Your session is about to expire
← Back to Search
Diuretic
Acetazolamide for Obstructive Sleep Apnea (RemmOSA Trial)
Phase 1 & 2
Recruiting
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 night
Summary
This trial will test a new treatment to reduce severity of OSA, a highly prevalent disorder with serious consequences. It will look at the effect of Acetazolamide on REM and nREM OSA and on ventilatory parameters.
Who is the study for?
This trial is for people with REM sleep apnea who haven't used CPAP for over a week. Participants should have more severe symptoms during REM than non-REM sleep and not be on any medication that affects breathing or have conditions like uncontrolled medical issues, major neurological disorders, heart failure, respiratory diseases other than sleep apnea, or be pregnant.
What is being tested?
The study tests if Acetazolamide can help with REM-related obstructive sleep apnea by improving muscle activity in the airway and breathing drive during sleep. It's compared to a placebo capsule to see if there's a real effect.
What are the potential side effects?
Acetazolamide may cause side effects such as acidosis (too much acid in the body), low potassium levels, low sodium levels, adrenal gland problems, kidney function impairment, allergic reactions if sensitive to sulfa drugs, liver disease complications.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 night
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 night
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Apnea hypopnea index
Genioglossus activity in REM and NREM
Hypoxia
+1 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: AcetazolamideActive Control1 Intervention
Acetazolamide 250 mg before bedtime 3 nights before the study, Acetazolamide 500 mg before bedtime for 2 nights before the study (inclusive)
Group II: PlaceboPlacebo Group1 Intervention
Placebo capsule before bedtime for 3 nights before the studies (inclusive)
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,670 Previous Clinical Trials
11,878,256 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have any uncontrolled medical conditions.I am currently taking the medication being studied.I am not taking medications that affect my breathing.I have a diagnosed sleep disorder like narcolepsy or frequent limb movements.I do not have any major conditions like heart failure or severe neurological disorders.I have a lung condition that is not sleep-related and causes low oxygen levels.I do not have conditions that react badly to acetazolamide or lidocaine/oxymetazoline, and I am not pregnant or nursing.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: Acetazolamide
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.